{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:20:40Z","timestamp":1788362440317,"version":"build-2803163510"},"reference-count":28,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Cardiol"],"abstract":"<jats:p>Antiplatelet pretreatment in patients with non-ST elevation acute coronary syndrome (NSTE-ACS) is controversial. It is vital that the risk of ischaemia and the risk of haemorrhage are both considered when managing this patient group. Current clinical guidelines do not recommend routine pretreatment in patients presenting with NSTE-ACS who are having coronary angiography within 24 hours. However, a significant portion of these patients will not have coronary angiography until after 24 hours. Pretreatment with antiplatelets may reduce the risk of ischaemic events, but it is associated with bleeding and delays to coronary artery bypass grafting, and it may be deleterious in patients with diagnoses other than NSTE-ACS, such as acute aortic syndromes, pulmonary embolism or intracranial bleeds. This review analyses the most important studies assessing antiplatelet pretreatment in NSTE-ACS.<\/jats:p>","DOI":"10.15420\/ecr.2026.10","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:50:01Z","timestamp":1788360601000},"source":"Crossref","is-referenced-by-count":0,"title":["Evidence-based Antiplatelet Pretreatment in Non\u2011ST\u2011elevation Acute Coronary Syndromes"],"prefix":"10.15420","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0750-1767","authenticated-orcid":false,"given":"Gabriel","family":"Torres-Ruiz","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02pg81z63","id-type":"ROR","asserted-by":"publisher"}],"name":"Corporaci\u00f3 Sanit\u00e0ria Parc Taul\u00ed"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3176-6191","authenticated-orcid":false,"given":"Jordi","family":"Sans-Rosell\u00f3","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02pg81z63","id-type":"ROR","asserted-by":"publisher"}],"name":"Corporaci\u00f3 Sanit\u00e0ria Parc Taul\u00ed"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6615-9231","authenticated-orcid":false,"given":"Eduard","family":"Bosch-Peligero","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02pg81z63","id-type":"ROR","asserted-by":"publisher"}],"name":"Corporaci\u00f3 Sanit\u00e0ria Parc Taul\u00ed"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9809-7112","authenticated-orcid":false,"given":"Paola","family":"Rojas-Flores","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02pg81z63","id-type":"ROR","asserted-by":"publisher"}],"name":"Corporaci\u00f3 Sanit\u00e0ria Parc Taul\u00ed"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2882-4100","authenticated-orcid":false,"given":"Andr\u00e9s","family":"Ribas-Closa","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02pg81z63","id-type":"ROR","asserted-by":"publisher"}],"name":"Corporaci\u00f3 Sanit\u00e0ria Parc Taul\u00ed"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1391-7108","authenticated-orcid":false,"given":"Manuel Alejandro","family":"Cabrera-Fern\u00e1ndez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02pg81z63","id-type":"ROR","asserted-by":"publisher"}],"name":"Corporaci\u00f3 Sanit\u00e0ria Parc Taul\u00ed"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3298-8362","authenticated-orcid":false,"given":"Pablo","family":"del Castillo-V\u00e1zquez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02pg81z63","id-type":"ROR","asserted-by":"publisher"}],"name":"Corporaci\u00f3 Sanit\u00e0ria Parc Taul\u00ed"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2070-4617","authenticated-orcid":false,"given":"Antoni","family":"Mart\u00ednez-Rubio","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02pg81z63","id-type":"ROR","asserted-by":"publisher"}],"name":"Corporaci\u00f3 Sanit\u00e0ria Parc Taul\u00ed"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045\u201357. https:\/\/doi.org\/10.1056\/NEJMoa0904327; PMID:\u00a019717846.","DOI":"10.1056\/NEJMoa0904327"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001\u201315. https:\/\/doi.org\/10.1056\/NEJMoa0706482; PMID:\u00a017982182.","DOI":"10.1056\/NEJMoa0706482"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Circulation 2018;138:e618\u201351. https:\/\/doi.org\/10.1161\/CIR.0000000000000617; PMID:\u00a030571511.","DOI":"10.1161\/CIR.0000000000000617"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Garcia-Garcia HM, McFadden EP, Farb A, et al. Standardized end point definitions for coronary intervention trials: the Academic Research Consortium-2 consensus document. Eur Heart J 2018;39:2192\u2013207. https:\/\/doi.org\/10.1093\/eurheartj\/ehy223; PMID:\u00a029897428.","DOI":"10.1093\/eurheartj\/ehy223"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Ducrocq G, Schulte PJ, Budaj A, et al. Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. Am Heart J 2017;186:91\u20139. https:\/\/doi.org\/10.1016\/j.ahj.2017.01.010; PMID:\u00a028454837.","DOI":"10.1016\/j.ahj.2017.01.010"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Sibbing D, Kastrati A, Berger PB. Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent? Eur Heart J 2016;37:1284\u201395. https:\/\/doi.org\/10.1093\/eurheartj\/ehv717; PMID:\u00a026712838.","DOI":"10.1093\/eurheartj\/ehv717"},{"key":"ref6","unstructured":"Sch\u00fcpke S, Neumann FJ, Menichelli M, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med 2019;381:1524\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1908973; PMID:\u00a031475799."},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 2013;369:999\u20131010. https:\/\/doi.org\/10.1056\/NEJMoa1308075; PMID:\u00a023991622.","DOI":"10.1056\/NEJMoa1308075"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Dworeck C, Redfors B, Anger\u00e5s O, et al. Association of pretreatment with P2Y12 receptor antagonists preceding percutaneous coronary intervention in non-ST-segment elevation acute coronary syndromes with outcomes. JAMA Netw Open 2020;3:e2018735. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.18735; PMID:\u00a033001202.","DOI":"10.1001\/jamanetworkopen.2020.18735"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607\u201321. https:\/\/doi.org\/10.1016\/S0140-6736(05)67660-X; PMID:\u00a016271642.","DOI":"10.1016\/S0140-6736(05)67660-X"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Mehta SR, Yusuf S, Peters RJG, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(01)05701-4; PMID:\u00a011520521.","DOI":"10.1016\/S0140-6736(01)05701-4"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494\u2013502. https:\/\/doi.org\/10.1056\/NEJMoa010746; PMID:\u00a011519503.","DOI":"10.1056\/NEJMoa010746"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Wiviott SD, Antman EM. Clopidogrel resistance: a new chapter in a fast-moving story. Circulation 2004;109:3064\u20137. https:\/\/doi.org\/10.1161\/01.CIR.0000134701.40946.30; PMID:\u00a015226220.","DOI":"10.1161\/01.CIR.0000134701.40946.30"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Gurbel PA, Bliden KP, Hiatt BL, O\u2019Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908\u201313. https:\/\/doi.org\/10.1161\/01.CIR.0000072771.11429.83; PMID:\u00a012796140.","DOI":"10.1161\/01.CIR.0000072771.11429.83"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Cattaneo M. Resistance to anti-platelet agents. Thromb Res 2011;127(Suppl 3):S61\u20133. https:\/\/doi.org\/10.1016\/S0049-3848(11)70017-2; PMID:\u00a021262444.","DOI":"10.1016\/S0049-3848(11)70017-2"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Wenaweser P, D\u00f6rffler-Melly J, Imboden K, et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005;45:1748\u201352. https:\/\/doi.org\/10.1016\/j.jacc.2005.01.058; PMID:\u00a015936599.","DOI":"10.1016\/j.jacc.2005.01.058"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation 2019;140:240\u201361. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.040167; PMID:\u00a031116032.","DOI":"10.1161\/CIRCULATIONAHA.119.040167"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"So DYF, Wells GA, Lordkipanidz\u00e9 M, et al. Early vs delayed bypass surgery in patients with acute coronary syndrome receiving ticagrelor: the RAPID CABG randomized open-label noninferiority trial. JAMA Surg 2025;160:387\u201394. https:\/\/doi.org\/10.1001\/jamasurg.2024.7066; PMID:\u00a039969871.","DOI":"10.1001\/jamasurg.2024.7066"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411\u201320. https:\/\/doi.org\/10.1001\/jama.288.19.2411; PMID:\u00a012435254.","DOI":"10.1001\/jama.288.19.2411"},{"key":"ref19","unstructured":"Di Sciascio G, Patti G, Pasceri V, et al. Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of Myocardial Damage During Angioplasty) randomized trial. J Am Coll Cardiol 2010;56:550\u20137. https:\/\/doi.org\/10.1016\/j.jacc.2010.01.067; PMID:\u00a020688209."},{"key":"ref20","unstructured":"Tarantini G, Mojoli M, Varbella F, et al. Timing of oral P2Y12 inhibitor administration in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol 2020;76:2450\u201359. https:\/\/doi.org\/10.1016\/j.jacc.2020.08.053; PMID:\u00a032882390."},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Torres-Ruiz G, Sans-Rosell\u00f3 J, Bosch-Peligero E, et al. Antiplatelet pretreatment effects in patients with non-ST-segment elevation acute coronary syndromes in a center without daily 24 hours access to the catheter laboratory. Heart Lung 2026;78:102728. https:\/\/doi.org\/10.1016\/j.hrtlng.2026.102728; PMID:\u00a041666635.","DOI":"10.1016\/j.hrtlng.2026.102728"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Stefanini GG, Vicenzi M. Stent thrombosis: prevention is the only effective treatment. EuroIntervention 2020;16:e279\u201381. https:\/\/doi.org\/10.4244\/EIJV16I4A48; PMID:\u00a032686652.","DOI":"10.4244\/EIJV16I4A48"},{"key":"ref23","unstructured":"Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021;42:1289\u2013367. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa575; PMID:\u00a032860058."},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"D\u00edez-Delhoyo F, L\u00f3pez Lluva MT, Cepas-Guill\u00e9n P, et al. Timing of coronary angiography and use of antiplatelet pretreatment in patients with NSTEACS in Spain. Rev Esp Cardiol 2024;77:234\u201342. https:\/\/doi.org\/10.1016\/j.recesp.2023.07.017.","DOI":"10.1016\/j.rec.2023.07.013"},{"key":"ref25","unstructured":"Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J 2023;44:3720\u2013826. https:\/\/doi.org\/10.1093\/eurheartj\/ehad191; PMID:\u00a037622654."},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Braunwald E, Morrow DA. Unstable angina: is it time for a requiem? Circulation 2013;127:2452\u20137. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.001258; PMID:\u00a023775194.","DOI":"10.1161\/CIRCULATIONAHA.113.001258"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Borovac JA, Leth-Olsen M, Kumric M, et al. Efficacy of high-dose atorvastatin or rosuvastatin loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials with GRADE qualification of available evidence. Eur J Clin Pharmacol 2022;78:111\u201326. https:\/\/doi.org\/10.1007\/s00228-021-03196-9; PMID:\u00a034423376.","DOI":"10.1007\/s00228-021-03196-9"}],"container-title":["European Cardiology Review"],"original-title":[],"link":[{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2026.10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:50:06Z","timestamp":1788360606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2026.10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":28,"URL":"https:\/\/doi.org\/10.15420\/ecr.2026.10","relation":{},"ISSN":["1758-3756","1758-3764"],"issn-type":[{"value":"1758-3756","type":"print"},{"value":"1758-3764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"e50"}}